RxDoctor Payments Data

Melissa Eline

Optometrist · Lancaster, PANPI 1588019434

Payments from drug & device makers

$1,824in general payments, 2019–2025

Across 78 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$473
  • Aerie Pharmaceuticals, Inc.$233
  • Bausch & Lomb Americas Inc.$199
  • Alcon$192
  • Tarsus Pharmaceuticals, Inc.$192
  • Sun Pharmaceutical Industries Inc.$159
  • plus $376 from 10 others

What the payments were for

  • Food & beverage$1,824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,824 in reported general payments places this provider in the 70th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,633
Medicare patients
467
Services billed
1,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine71$59,335
XiidraLifitegrast46$42,419
LumiganBimatoprost96$38,872
RhopressaNetarsudil Mesylate78$34,266
RocklatanNetarsudil Mesylat/Latanoprost67$28,779
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol94$16,096
CombiganBrimonidine Tartrate/Timolol38$13,143
Cyclosporine26$9,935
Latanoprost1,147$7,855
VyzultaLatanoprostene Bunod22$6,615
Brimonidine Tartrate230$6,519
Brinzolamide25$5,702
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat248$4,373
Timolol Maleate215$3,158
SimbrinzaBrinzolamide/Brimonidine Tart15$2,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$473$111,350205 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$233$63,045145 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$199$49,03368 claims
AlconSimbrinza$192$2,89315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →